<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have compared two classes of putative neuroprotectants, the voltage-dependent <z:chebi fb="1" ids="29101">Na+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> BW619C87 [4-amino-2-(4-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-piperazinyl)-5-(2,3,5-trichlorophenyl) <z:chebi fb="0" ids="16898">pyrimidine</z:chebi>], and the voltage-dependent <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> nimodipine, in a rat model of transient focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>BW619C87 (10-50 mg/kg) or nimodipine (10-100 microg/kg) were injected intravenously 5 min before induction of 2 h transient focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> via intraluminal thread occlusion of the middle cerebral artery </plain></SENT>
<SENT sid="2" pm="."><plain>BW619C87 was a potent neuroprotectant over the range tested, maximally reducing the volume of hemispheric ischaemic damage by 51% at the 50 mg/kg dose </plain></SENT>
<SENT sid="3" pm="."><plain>Nimodipine maximally reduced ischaemic damage by 33% at the 50 microg/kg dose, although the maximal level of neuroprotection afforded by BW619C89 and nimodipine was not significantly different </plain></SENT>
<SENT sid="4" pm="."><plain>This is the first study to compare these two classes of drug directly in a model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion, and it supports the effectiveness of both as neuroprotectants </plain></SENT>
</text></document>